Form: 3

Initial statement of beneficial ownership of securities

December 22, 2022

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
ODONNELL FRANCIS E JR
(Last) (First) (Middle)
C/O INHIBITOR THERAPUTICS, INC.,
900 WEST PLATT ST, SUITE 200
(Street)
TAMPA FL 33606
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/13/2022 		3. Issuer Name and Ticker or Trading Symbol
Inhibitor Therapeutics, Inc. [ INTI ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 85,627,069 I See Footnotes(1)(2)(3)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares represent 6,000,000 shares of common stock held by Hopkins Capital Group II, LLC ("HCG II LLC") and 79,627,069 shares of common stock held by Hedgepath, LLC ("HP LLC").
2. Francis E. O'Donnell Irrevocable Trust #1 owns 28.12% of HCG II LLC and Francis E. O'Donnell Descendants Trust owns 3.13% of HCG II LLC. Kathleen M . O'Donnell, Dr. O'Donnell's sister, is the trustee of Francis E. O'Donnell Irrevocable Trust #1 and Francis E. O'Donnell Descendants Trust. Dr. O'Donnell does not have voting and dispositive control over any of these shares and disclaims any beneficial ownership of the reported shares held by HCG II LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
3. The Francis E. O'Donnell Jr. Irrevocable Trust #7 owns 26.5% of HP LLC. Kathleen M. O'Donnell, Dr. O'Donnell's sister, is the trustee of HP LLC. Dr. O'Donnell does not have voting and dispositive control over any of these shares and disclaims any beneficial ownership of the reported shares held by HP LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
Remarks:
Chief Executive Officer, Executive Chairman of the Board
/s/ Francis O'Donnell 12/22/2022
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.